Invero Pharma believes xenon holds great promise due to its multiple mechanisms of action, extensive pre-clinical results² and positive Phase II clinical trial results which demonstrated a reduction in brain tissue damage and directionally better survival outcomes. Invero Pharma intends to become a leader in the development and commercialization of drug/device neuroprotective products that help prevent brain damage and improve mortality rates in patient populations experiencing acute injury to the brain. ¹ Laitio et. al. ,JAMA. 2016;315(11):1120-1128. doi:10.1001/jama.2016.1933 ² Maze, Can J Anesth/J Can Anesth. DOI 10.1007/s12630-015-0507-8